These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19398598)

  • 1. Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
    Amir E; Trinkaus M; Simmons CE; Dranitsaris G; Clemons MJ
    J Clin Pathol; 2009 May; 62(5):474-6. PubMed ID: 19398598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
    Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
    Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
    Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
    Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
    Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA
    Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
    Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
    Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
    Broom R; Du H; Clemons M; Eton D; Dranitsaris G; Simmons C; Ooi W; Cella D
    J Pain Symptom Manage; 2009 Aug; 38(2):244-57. PubMed ID: 19364633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
    Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
    Wood J; Bonjean K; Ruetz S; Bellahcène A; Devy L; Foidart JM; Castronovo V; Green JR
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1055-61. PubMed ID: 12183663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
    Vincenzi B; Santini D; Dicuonzo G; Battistoni F; Gavasci M; La Cesa A; Grilli C; Virzì V; Gasparro S; Rocci L; Tonini G
    J Interferon Cytokine Res; 2005 Mar; 25(3):144-51. PubMed ID: 15767788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
    Lowery AJ; Sweeney KJ; Molloy AP; Hennessy E; Curran C; Kerin MJ
    BMC Cancer; 2008 Sep; 8():279. PubMed ID: 18826631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
    Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
    Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.